ArticleRadiation oncology (London, England)2018
The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
Article in Radiation oncology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary.International journal of radiation oncology, biology, physics · 2025Guideline
- Segmental bronchi radiation dose affected the progression of radiation pneumonitis in lung cancer patients.Discover oncology · 2025Article
- Development of a predictive model for radiation pneumonitis based on plasma exosomal miR-200b-5p.Frontiers in oncology · 2025Article
- Volumetric modulated arc therapy (VMAT) comparison to 3D-conformal technique in lung stereotactic ablative radiotherapy (SABR).Journal of medical radiation sciences · 2023Article
- Quantitative Assessment and Comparative Analysis of Longitudinal Lung CT Scans of Chest-Irradiated Nonhuman Primates.Radiation research · 2023Article
- Re-irradiation for intra-thoracic tumours and extra-thoracic breast cancer: dose accumulation, evaluation of efficacy and toxicity based on a literature review.The British journal of radiology · 2022Review
- Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.BMC pulmonary medicine · 2022Article
- Radiomic and Dosiomic Features for the Prediction of Radiation Pneumonitis Across Esophageal Cancer and Lung Cancer.Frontiers in oncology · 2022Article
- Biological dosiomic features for the prediction of radiation pneumonitis in esophageal cancer patients.Radiation oncology (London, England) · 2021Article
- Radiation-Induced Lung Injury-Current Perspectives and Management.Clinics and practice · 2021Review
- Radiation-induced lung injury: current evidence.BMC pulmonary medicine · 2021Review
- Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer.Clinical and translational radiation oncology · 2020Article
- Prognostic factors and outcome of reirradiation for locally recurrent small cell lung cancer-a multicenter study.Translational lung cancer research · 2020Article
- Provider decision regret-a useful method for analysis of palliative thoracic re-irradiation for lung cancer?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Article
- Validation of in-house knowledge-based planning model for advance-stage lung cancer patients treated using VMAT radiotherapy.The British journal of radiology · 2020Article
- Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020Article
- Re-irradiation volumetric modulated arc therapy optimization based on cumulative biologically effective dose objectives.Journal of applied clinical medical physics · 2018Article
- Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis.Radiation oncology (London, England) · 2018Article
- Relationship Between Radiation Pneumonitis Following Definitive Radiotherapy for Non-small Cell Lung Cancer and Isodose Line.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThoracic reirradiation (re-RT) is increasingly administered. However, radiation pneumonitis (RP) remains to be the most common side effect from retreatment. This study aimed to determine the risk and predictors for severe RP in patients receiving thoracic re-RT.
methodsSixty seven patients with lung cancer received thoracic re-RT for recurrent or metastatic disease. Three-dimensional conformal radiotherapy (3D-CRT)/intensity modulated radiotherapy (IMRT) was used for 60 patients, and stereotactic body radiation therapy (SBRT) was used in 7 patients. Deformable image registration (DIR) was performed to create a composite plan. Severe (grade ≥ 3) RP was graded according to Common Terminology Criteria for Adverse Events version 4.0.
resultsEighteen patients (26.9%) developed grade ≥ 3 RP (17 of grade 3, and 1 of grade 4). In univariate analyses, V5 and mean lung dose (MLD) of initial RT or re-RT plans, V5 and V20 of composite plans, and the overlap between V5 of initial RT and V5 of re-RT plans/V5 of re-RT plans (overlap-V5/re-V5) were significantly associated with grade ≥ 3 RP (P < 0.05 for each comparison). Multivariate analysis revealed that MLD of the initial RT plans (HR = 14.515, 95%CI:1.778-118.494, P = 0.013), V5 of the composite plans (HR = 7.398, 95%CI:1.319-41.495, P = 0.023), and overlap-V5/re-V5 (P = 0.041) were independent predictors for grade ≥ 3 RP. Out-of-field failures with medium overlap-V5/re-V5 of 0.4-0.8 was associated with higher risk of grade ≥ 3 RP compared with in-field failures (18.3% vs. 50%, P = 0.014).
conclusionsThe risk of grade ≥ 3 RP could be predicted not only by dose-volume variables from re-RT plan, but also by some from initial-RT and composite plans. Out-of-field failures was associated with higher risk of severe RP compared with in-field failures in some cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.